Showing 3711-3720 of 5910 results for "".
- Horizon Surgical Systems Announces World’s First Robotic Cataract Surgery Using the Polaris Platformhttps://modernod.com/news/horizon-surgical-systems-announces-worlds-first-robotic-cataract-surgery-using-the-polaris-platform/2484160/Horizon Surgical Systems announced the completion of the world’s first cataract surgery performed using its Polaris robotic platform. The milestone procedure was conducted by Uday Devgan, MD, FACS.
- Regenxbio Completes Enrollment in ATMOSPHERE and ASCENT Trials of Sura-Vec Gene Therapy for Wet AMDhttps://modernod.com/news/regenxbio-completes-enrollment-in-atmosphere-and-ascent-trials-of-sura-vec-gene-therapy-for-wet-amd/2484155/Regenxbio announced the completion of enrollment in its two pivotal phase 3 studies—ATMOSPHERE and ASCENT—evaluating surabgene lomparvovec (sura-vec, ABBV-RGX-314), an investigational one-time gene therapy for wet age-related macular degeneration (
- Virtual Field Launches DICOM 360 Sync Connectivity Hubhttps://modernod.com/news/virtual-field-launches-dicom-360-sync-connectivity-hub/2484151/Virtual Field announced the launch of DICOM 360 Sync, a connectivity hub that aims to redefine how practices connect diagnostics with medical records. DICOM 360 Sync is designed to deliver instant, autom
- Cirrus Therapeutics Raises $11 Million to Advance First-in-Class Ocular Gene Therapy Targeting Dry AMDhttps://modernod.com/news/cirrus-therapeutics-raises-11-million-to-advance-first-in-class-ocular-gene-therapy-targeting-dry-amd/2484149/Cirrus Therapeutics announced the close of an $11 million seed financing round to advance its gene and cell therapy pipeline. The company will use the funds to progress its lead program into IND-enabling studies.
- Kalaris Therapeutics Launches Phase 1b/2 Dose-Finding Trial of TH103 for Wet AMDhttps://modernod.com/news/kalaris-therapeutics-launches-phase-1b2-dose-finding-trial-of-th103-for-wet-amd/2484144/Kalaris Therapeutics has initiated patient enrollment in a phase 1b/2 multiple ascending dose (MAD) clinical study of TH103, its investigational therapy for wet age-related macular degeneration (AMD). The phase 1b/2 t
- The Vision Council Releases Focused inSights 2025: Smart Eyewearhttps://modernod.com/news/the-vision-council-releases-focused-insights-2025-smart-eyewear/2484143/The Vision Council announced the release of 'Focused inSights 2025: Smart Eyewear,' a consumer research report that highlights growing interest and evolving attitudes toward the developing smart eyewear category. Drawing on survey responses from more than 4
- Neurolens, Maker of Contoured Prism Technology, Rebrands as Newtonhttps://modernod.com/news/neurolens-maker-of-contoured-prism-technology-rebrands-as-newton/2484138/Neurolens announced its official rebrand to Newton. Named in honor of Sir Isaac Newton, the company said the rebrand reflects Newton’s broader vision to build on its foundation of innovative lens technology and continue driving outcomes that help pa
- Valitor Presents Preclinical Safety Data on Long-Acting Anti-VEGF VLTR-559 for Wet AMDhttps://modernod.com/news/valitor-presents-preclinical-safety-data-on-long-acting-anti-vegf-vltr-559-for-wet-amd/2484137/Valitor announced new preclinical data on VLTR-559, its long-acting anti-VEGF biologic in development for wet age-related macular degeneration (AMD). The findings were featured in a presentation at the Ophthalmology Futures Retina Forum.
- Ashvattha Therapeutics Reports Positive Phase 2 Results for Potential First-in-Class Treatment for DME and Wet AMDhttps://modernod.com/news/ashvattha-therapeutics-reports-positive-phase-2-results-for-potential-first-in-class-treatment-for-dme-and-wet-amd/2484136/Ashvattha Therapeutics announced positive topline results from its phase 2 study of migaldendranib (MGB) in diabetic macular edema (DME) and wet age-related macular degeneration (AMD) at the Euretina Congress. MGB is
- PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025https://modernod.com/news/pulsesight-therapeutics-to-present-new-data-on-iron-dysregulation-and-ferroptosis-in-amd-at-euretina-2025/2484133/PulseSight Therapeutics announced that its Chief Scientific Officer, Thierry Bordet, PhD, will present new clinical and preclinical findings on the role of iron dysregulation and ferroptosis in age-related macular degeneration (AMD) at the 25th Euretina Congre